Developer docs
API playgroundTry for free, no card

Search company profiles

Quantigen

Full company profile

uuid000eemf

Namestring
Quantigen
Legal namestring
Quantigen Biosciences
Websiteurl
quantigen.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Quantigen Biosciences is a contract research organization and patient diagnostic laboratory founded in 2008 and headquartered in a 40,000-square-foot high-throughput facility in Fishers, Indiana. The company specializes in sample-to-answer method development and validation across three core application areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics. Its service portfolio spans biomarker and assay development including HLA typing, companion diagnostic (CDx) assay development, molecular diagnostics and infectious disease testing, clinical trial management, central laboratory services, and quality and regulatory services. The underlying technology leverages molecular biology, biotechnology, and regulatory oversight expertise to design customized, cost-effective workflows, supported by ISO 15189 accreditation.

Quantigen generates revenue through project-based contract research and assay development engagements sold directly to pharmaceutical and biotechnology companies, academic and institutional researchers, IVD developers, and medical device manufacturers. Pricing is not publicly disclosed and is typically quoted based on project scope. The company operates within a horizontal segmentation model, with therapeutic developers as the primary customer segment. Geographic reach is concentrated in the Midwest United States, with operations anchored in the Fishers, Indiana life sciences cluster.

In July 2023, Quantigen was acquired by Versiti Clinical Trial Services, a 501(c)(3) nonprofit organization, and was integrated into a unified platform alongside Pearl IRB, Salus IRB, Cenetron, and Pearl Pathways. The standalone Quantigen and Pearl Pathways websites were retired as part of the consolidation. Operating headcount is reported at 11-50 employees, and the company is now wholly owned by Versiti with no disclosed outside institutional or private equity investors.

Short descriptiontext

Quantigen is a contract research organization and diagnostic laboratory specializing in sample-to-answer assay development, companion diagnostics, and molecular diagnostics for pharmaceutical, biotech, IVD, and academic clients. Founded in 2008, it operates from a 40,000 sq ft ISO 15189-accredited facility in Fishers, Indiana, and was acquired by Versiti Clinical Trial Services in July 2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFishers, United States
HQ citystring
Fishers
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, assay development services, companion diagnostics, biomarker analysis, molecular diagnostics testing
Industry4 codes
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAJ
Companion Diagnostics (CDx) & Precision Medicine IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code4 codes
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Contract Research and Diagnostic Laboratory Services
Social media profiles1 record
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Quantigen is a contract research organization and diagnostic laboratory that delivers sample-to-answer method development and validation across biomarker assay design, HLA typing, companion diagnostics, molecular diagnostics and infectious disease testing. The company operates a 40,000-square-foot ISO 15189-accredited high-throughput facility in Fishers, Indiana, serving pharmaceutical, biotechnology, IVD developer, medical device and academic clients through three core capability areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Quantigen operates as a high-throughput contract research and assay development organization offering integrated scientific services within the Versiti Clinical Trial Services family. Founded in 2008 and acquired by Versiti in July 2023, Quantigen specializes in sample-to-answer method development and validation across three core areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics. The product portfolio comprises six interconnected service offerings—Biomarker/Assay Development & HLA Typing, Companion Diagnostics, Molecular Diagnostics & Infectious Disease Testing, Clinical Trial Management, Laboratory & Diagnostic Services, and Quality & Regulatory Services—all designed to accelerate diagnostic innovation from discovery through deployment. These services are delivered from a 40,000-square-foot facility in Fishers, Indiana, and leverage expertise in molecular biology, biotechnology, and regulatory oversight to design customized, cost-effective workflows for clients.

Product and service1 record
1Biomarker, Assay Development & HLA Typing
CategoryLaboratory & Diagnostic Services
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-01
Description

In July 2023, Quantigen joined the Versiti Clinical Trial Services family, expanding its reach and integrating its robust capabilities within a broader clinical trials ecosystem. Quantigen became part of Versiti's portfolio of clinical trial services brands including Pearl IRB, Salus IRB, Cenetron, and Pearl Pathways, operating under a unified Versiti Clinical Trial Services platform.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Specialty bioanalytical and biomarker CRO offering large-molecule bioanalysis, immunogenicity, cell-based assays, and biomarker services for pharma/biotech. Highly comparable to Quantigen's biomarker, assay development, and immunogenicity capabilities serving similar therapeutic developers.

TypeDirect peer
Description

Global central laboratory services for clinical trials, including biomarker analysis, specialty immunology, and molecular diagnostics. Directly comparable to Quantigen's central lab and clinical diagnostics service line within a CRO/trial-support framework.

TypeDirect peer
Description

Central and specialty laboratory services for clinical trials spanning genomics, biomarkers, flow cytometry, and anatomic pathology. Closely aligned with Quantigen's molecular diagnostics, biomarker, and HLA/immunogenetics offerings for trial sponsors.

TypeDirect peer
Description

Provides central laboratory and biomarker services for global clinical trials, with capabilities in immunoassays, flow cytometry, and molecular diagnostics. Comparable to Quantigen's central lab role for therapeutic development programs.

TypeDirect peer
Description

Specialty oncology and molecular diagnostics laboratory providing clinical trial and CDx services to pharma/biotech. Comparable to Quantigen's molecular diagnostics, oncology focus, and CDx development capabilities.

TypeDirect peer
Description

Contract research organization offering bioanalytical, biomarker, and CMC services to pharma and biotech. Comparable to Quantigen in providing regulated assay development and validation for therapeutic development.

TypeBroad incumbent
Description

Large CRO and central lab operator (post-Fortrea spin) with broad biomarker, CDx, and central lab capabilities. Comparable in service scope but materially larger and globally distributed than Quantigen.

TypeBroad incumbent
Description

Global CRO and central/biomarker laboratory serving pharmaceutical R&D and clinical trials across the full lifecycle. Comparable category (CRO + central lab) but operates at vastly greater scale and geographic reach.

TypeBroad incumbent
Description

Large CRO with discovery, safety assessment, and CDx/biomarker service lines. Overlaps with Quantigen's biomarker and CDx work but operates as a broad incumbent with a much larger portfolio.

TypeRegional player
Description

Central laboratory serving European-based clinical trials with biomarker and specialty testing. Comparable central lab services to Quantigen but primarily European geography, providing an indirect competitive benchmark.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quantigen

Contract Research and Diagnostic Laboratory Servicesquantigen.com

Quantigen is a contract research organization and diagnostic laboratory specializing in sample-to-answer assay development, companion diagnostics, and molecular diagnostics for pharmaceutical, biotech, IVD, and academic clients. Founded in 2008, it operates from a 40,000 sq ft ISO 15189-accredited facility in Fishers, Indiana, and was acquired by Versiti Clinical Trial Services in July 2023.

What Quantigen does

Quantigen Biosciences is a contract research organization and patient diagnostic laboratory founded in 2008 and headquartered in a 40,000-square-foot high-throughput facility in Fishers, Indiana. The company specializes in sample-to-answer method development and validation across three core application areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics. Its service portfolio spans biomarker and assay development including HLA typing, companion diagnostic (CDx) assay development, molecular diagnostics and infectious disease testing, clinical trial management, central laboratory services, and quality and regulatory services. The underlying technology leverages molecular biology, biotechnology, and regulatory oversight expertise to design customized, cost-effective workflows, supported by ISO 15189 accreditation.

Quantigen generates revenue through project-based contract research and assay development engagements sold directly to pharmaceutical and biotechnology companies, academic and institutional researchers, IVD developers, and medical device manufacturers. Pricing is not publicly disclosed and is typically quoted based on project scope. The company operates within a horizontal segmentation model, with therapeutic developers as the primary customer segment. Geographic reach is concentrated in the Midwest United States, with operations anchored in the Fishers, Indiana life sciences cluster.

In July 2023, Quantigen was acquired by Versiti Clinical Trial Services, a 501(c)(3) nonprofit organization, and was integrated into a unified platform alongside Pearl IRB, Salus IRB, Cenetron, and Pearl Pathways. The standalone Quantigen and Pearl Pathways websites were retired as part of the consolidation. Operating headcount is reported at 11-50 employees, and the company is now wholly owned by Versiti with no disclosed outside institutional or private equity investors.

Quantigen firmographics

Firmographics
Name
Quantigen
Legal name
Quantigen Biosciences
Website
https://quantigen.com
Company type
Private
Founded year
2008
Operating status
Acquired
Headcount range
11–50 employees
Short description
Quantigen is a contract research organization and diagnostic laboratory specializing in sample-to-answer assay development, companion diagnostics, and molecular diagnostics for pharmaceutical, biotech, IVD, and academic clients. Founded in 2008, it operates from a 40,000 sq ft ISO 15189-accredited facility in Fishers, Indiana, and was acquired by Versiti Clinical Trial Services in July 2023.
Ownership category
akta.pro rank

Quantigen industry classification

Industry
Product category
Contract Research and Diagnostic Laboratory Services
NAICS
Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAHAAAJ
Companion Diagnostics (CDx) & Precision Medicine IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAHAAAD
Molecular Diagnostics (PCR/NAAT/NGS-based IVD)
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Contract research services
  • Assay development services
  • Companion diagnostics
  • Biomarker analysis
  • Molecular diagnostics testing

Where Quantigen is headquartered

Location

Headquarters

HQ city
Fishers
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Quantigen business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Distribution channels2 records

Marketing channels3 records

Quantigen product offering

Product offering

Core offering

Quantigen is a contract research organization and diagnostic laboratory that delivers sample-to-answer method development and validation across biomarker assay design, HLA typing, companion diagnostics, molecular diagnostics and infectious disease testing. The company operates a 40,000-square-foot ISO 15189-accredited high-throughput facility in Fishers, Indiana, serving pharmaceutical, biotechnology, IVD developer, medical device and academic clients through three core capability areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics.

Product overview

Quantigen operates as a high-throughput contract research and assay development organization offering integrated scientific services within the Versiti Clinical Trial Services family. Founded in 2008 and acquired by Versiti in July 2023, Quantigen specializes in sample-to-answer method development and validation across three core areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics. The product portfolio comprises six interconnected service offerings—Biomarker/Assay Development & HLA Typing, Companion Diagnostics, Molecular Diagnostics & Infectious Disease Testing, Clinical Trial Management, Laboratory & Diagnostic Services, and Quality & Regulatory Services—all designed to accelerate diagnostic innovation from discovery through deployment. These services are delivered from a 40,000-square-foot facility in Fishers, Indiana, and leverage expertise in molecular biology, biotechnology, and regulatory oversight to design customized, cost-effective workflows for clients.

Differentiator

Problem solved

Functional benefit

Products and services

  • Biomarker, Assay Development & HLA Typing

Companies that use Quantigen

Customer profile

Segments4 records

Ideal customer profiles3 records

Quantigen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Quantigen partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Versiti Clinical Trial ServicescoreStrategic or Co-development Partner · 1 July 2023In July 2023, Quantigen joined the Versiti Clinical Trial Services family, expanding its reach and integrating its robust capabilities within a broader clinical trials ecosystem. Quantigen became part of Versiti's portfolio of clinical trial services brands including Pearl IRB, Salus IRB, Cenetron, and Pearl Pathways, operating under a unified Versiti Clinical Trial Services platform.

Scale indicators3 records

Recent moves4 records

Expansion highlights3 records

Quantigen competitors and assessment

Company assessment

Direct peers

  • BioAgilytix Labs: Specialty bioanalytical and biomarker CRO offering large-molecule bioanalysis, immunogenicity, cell-based assays, and biomarker services for pharma/biotech. Highly comparable to Quantigen's biomarker, assay development, and immunogenicity capabilities serving similar therapeutic developers.
  • Eurofins Central Laboratory: Global central laboratory services for clinical trials, including biomarker analysis, specialty immunology, and molecular diagnostics. Directly comparable to Quantigen's central lab and clinical diagnostics service line within a CRO/trial-support framework.
  • Q² Solutions (IQVIA/Quest Joint Venture): Central and specialty laboratory services for clinical trials spanning genomics, biomarkers, flow cytometry, and anatomic pathology. Closely aligned with Quantigen's molecular diagnostics, biomarker, and HLA/immunogenetics offerings for trial sponsors.
  • ICON Central Laboratories: Provides central laboratory and biomarker services for global clinical trials, with capabilities in immunoassays, flow cytometry, and molecular diagnostics. Comparable to Quantigen's central lab role for therapeutic development programs.
  • NeoGenomics Laboratories: Specialty oncology and molecular diagnostics laboratory providing clinical trial and CDx services to pharma/biotech. Comparable to Quantigen's molecular diagnostics, oncology focus, and CDx development capabilities.
  • Frontage Laboratories: Contract research organization offering bioanalytical, biomarker, and CMC services to pharma and biotech. Comparable to Quantigen in providing regulated assay development and validation for therapeutic development.

Broad incumbents

  • Labcorp (Fortrea) Clinical Development & Central Labs: Large CRO and central lab operator (post-Fortrea spin) with broad biomarker, CDx, and central lab capabilities. Comparable in service scope but materially larger and globally distributed than Quantigen.
  • IQVIA Laboratories: Global CRO and central/biomarker laboratory serving pharmaceutical R&D and clinical trials across the full lifecycle. Comparable category (CRO + central lab) but operates at vastly greater scale and geographic reach.
  • Charles River Laboratories: Large CRO with discovery, safety assessment, and CDx/biomarker service lines. Overlaps with Quantigen's biomarker and CDx work but operates as a broad incumbent with a much larger portfolio.

Regional players

  • BARC Global Central Laboratory: Central laboratory serving European-based clinical trials with biomarker and specialty testing. Comparable central lab services to Quantigen but primarily European geography, providing an indirect competitive benchmark.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Quantigen social profiles

Digital presence

Quantigen compliance and trust

Trust signal

Compliance1 record

Quantigen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quantigen leadership team

Management profile

Number of profiles

Quantigen funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quantigen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quantigen

What does Quantigen do?

Quantigen is a contract research organization and diagnostic laboratory that delivers sample-to-answer method development and validation across biomarker assay design, HLA typing, companion diagnostics, molecular diagnostics and infectious disease testing. The company operates a 40,000-square-foot ISO 15189-accredited high-throughput facility in Fishers, Indiana, serving pharmaceutical, biotechnology, IVD developer, medical device and academic clients through three core capability areas: Basic and Preclinical Research, Clinical and Translational Research, and Clinical Diagnostics.

Is Quantigen a public or private company?

Quantigen is a private company. It is classified as nonprofit foundation owned and is currently acquired.

When was Quantigen founded?

Quantigen was founded in 2008. It employs 11 to 50 people.

Where is Quantigen based?

Quantigen is headquartered in Fishers, United States, in the North America region.

Who are Quantigen's main competitors?

Direct peers on record are BioAgilytix Labs, Eurofins Central Laboratory, Q² Solutions (IQVIA/Quest Joint Venture), ICON Central Laboratories, NeoGenomics Laboratories and Frontage Laboratories. Broad incumbents are Labcorp (Fortrea) Clinical Development & Central Labs, IQVIA Laboratories and Charles River Laboratories. BARC Global Central Laboratory is listed as a regional player.

Does Quantigen have an API?

No public API is recorded for Quantigen.

What industry is Quantigen in?

Quantigen's product category is Contract Research and Diagnostic Laboratory Services. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Inside Indiana BusinessFrom quiet powerhouse to talent magnet: How Indiana can compete with coastal life sciences hubs – Inside INdiana BusinessThe author argues that Indiana has the foundational ingredients—a collaborative culture, existing anchor institutions, and talent—to build a life sciences ecosystem that can rival coastal hubs, but must address two key weaknesses: slower business tempo and limited access to early-stage capital. The article cites Fishers as a model of successful cluster development, where companies including INCOG BioPharma, Genezen, 1Elevan Biopharmaceuticals, Telix Pharmaceuticals, and Quantigen Biosciences have established operations, demonstrating that targeted local strategy can attract and retain life sciences employers. The author proposes that Indiana allocate a portion of its $50 billion state employee pension funds to invest in Indiana life sciences companies and specialized funds as a disciplined approach to aligning long-term capital with economic interests.BizTimesVersiti acquires Indiana-based QuantigenVersiti announced the acquisition of Quantigen, an Indiana-based specialty laboratory specializing in preclinical research and clinical diagnostics. This transaction is intended to expand Versiti’s clinical trial expertise and service offerings across various disease states and the drug development pathway.PR NewswireVersiti Acquires Indiana-based QuantigenVersiti announced the acquisition of Quantigen, an Indiana-based specialty lab, to expand its clinical trial expertise and service offerings in preclinical and clinical research. This strategic move adds complementary capabilities in assay development and diagnostic regulatory filings to Versiti's existing portfolio, following previous acquisitions such as Cenetron Central Laboratories. The transaction aims to strengthen Versiti's position across the drug and medical device development pathway from pre-clinical stages to commercialization.SlashGearFDA: Q-Tip-Style Swab Could Cut Coronavirus Test RiskThe FDA is considering a new Q-tip-style swab for COVID-19 testing, developed by U.S. Cotton, which could enable at-home tests and reduce healthcare provider workload. The swab uses a polyester tip and can be produced in large quantities, with a study led by UnitedHealth, Quantigen, and the Gates Foundation. The FDA is working with developers on at-home kits, but sample collection and shipping concerns remain.PR NewswireCoronavirus (COVID-19) Update: FDA, Gates Foundation, UnitedHealth Group, Quantigen, and U.S. Cotton Collaborate to Address Testing Supply NeedsThe U.S. Food and Drug Administration (FDA) announced the recognition of spun synthetic swabs for COVID-19 testing, a development enabled by a collaboration involving UnitedHealth Group, Quantigen, the Gates Foundation, and U.S. Cotton. U.S. Cotton, a subsidiary of Parkdale-Mills, developed these polyester-based swabs to be manufactured at scale in the U.S., addressing critical supply needs for diagnostic testing. This partnership allows for patient self-collection of samples, aiming to expand testing capabilities domestically and globally.